Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 4, 1997

View Archived Issues

Chiron: Q3 1997 highlights

Sequus: Q3 1997 highlights

SangStat Medical: Q3 1997 highlights

Celgene: Q3 1997 highlights

Bausch & Lomb to acquire Chiron Vision

Promising phase III results reported for KeraVision ring

Factor Xa inhibitors prepared at DuPont Merck

NeuroSearch describes tropane derivatives that inhibit neurotransmitter reuptake

Novel class of compound enhances IFN-gamma and NT-3 activity

HMR claims dual H1/NK1 antagonists for allergic/inflammatory disorders

Bristol-Myers Squibb prepares protein farnesyltransferase inhibitors

New alpha-1-antitrypsin test launched in U.S.

Chiroscience develops new TNF/PDE IV inhibitors

Clinical trials planned for CEP-1347/KT-7515 in AD

Sequana and Glaxo Wellcome revise diabetes/obesity alliance

Oral prodrugs of novel carbapenems prepared at Wyeth-Ayerst

Preclinical results with Ergo Science's neuroendocrine resetting therapy

Phase III safety and efficacy data reported for one-alpha D2

GelTex submits NDA for RenaGel

Arris and Sequana to merge

New human rabies vaccine cleared in U.S.

Novel antihypertensive agent developed in Taiwan

Effects of riluzole on ischemia-induced glutamate accumulation in rabbits

U.S. patent issued for ABS 200 series

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...